Botulinum neurotoxin for pain management: Insights from animal models

Toxins

Volumn 2, Issue 12, 2010, Pages 2890-2913

  Pavone, Flaminia ^a   Luvisetto, Siro ^a  

^a CNR   (Italy)

Author keywords

Analgesia; Animal model; Botulinum toxin; Central sensitization; Chronic pain; Inflammatory pain; Pain; Peripheral sensitization; Retrograde axonal transport; SNARE

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CALCITONIN GENE RELATED PEPTIDE; CARRAGEENAN; NEUROTRANSMITTER; SNARE PROTEIN; SUBSTANCE P; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ANALGESIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTHRITIS; BINDING AFFINITY; CELL FUNCTION; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG SENSITIZATION; HINDPAW INJURY; HIP INJURY; HYPERACTIVITY; HYPERALGESIA; INTERNALIZATION; INTERVERTEBRAL DISK HERNIA; MIGRAINE; MULTIPLE SCLEROSIS; MUSCLE RELAXATION; MYOFASCIAL PAIN; NEUROMUSCULAR SYNAPSE; NEUROPATHIC PAIN; NEUROPATHY; NONHUMAN; PAIN; PAIN ASSESSMENT; PATHOGENESIS; PAW EDEMA; PERIPHERAL NEUROPATHY; POSTHERPETIC NEURALGIA; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN TRANSPORT; REVIEW; SEROTYPE; SINGLE DRUG DOSE; TRIGEMINUS NEURALGIA; VISCERAL PAIN;

ANIMALS; BOTULINUM TOXINS; DISEASE MODELS, ANIMAL; HUMANS; NEUROTOXINS; PAIN; PAIN MANAGEMENT;

ANIMALIA;

EID: 79952097579     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins2122890     Document Type: Review

References (126)

1. Simpson, L.L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol. Rev. 1981, 33, 155-188.
2. Gill, D.M. Bacterial toxins: A table of lethal amounts. Microbiol. Rev. 1982, 46, 86-94.
3. Smith, L.D.S.; Sugiyama, H. Botulism: The Organism, Its Toxins, the Disease, 2nd ed.; Charles C. Thomas, Publisher Ltd.: Springfield, IL, USA, 1988.
4. Hatheway, C.L. Botulism: The present status of the disease. Curr. Top. Microbiol. Immunol. 1995, 195, 55-75.
5. Cherington, M. Clinical spectrum of botulism. Muscle Nerve 1988, 21, 701-710.
6. Sobel, J. Botulism. Clin. Infect. Dis. 2005, 41, 1167-1173.
7. Erbguth, F.J. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov. Disord. 2004, 19, S2-S6.
8. Jankovic, J.; Brin, M.F. Botulinum Toxin: Historical Perspective and Potential New Indications. Muscle Nerve 1997, 20, S129-S145.
9. Montecucco, C.; Molgò, J. Botulinal neurotoxins: Revival of an old killer. Curr. Opin. Pharmacol. 2005, 5, 274-279.
10. Truong, D.D.; Jost, W.H. Botulinum toxin: Clinical use. Parkinsonism Relat. Disord. 2006, 12, 331-355.
11. Jabbari, B. Botulinum neurotoxins in the treatment of refractory pain. Nature Clin. Pract. Neurology. 2008, 4, 676-685.
12. Montecucco, C.; Schiavo, G.; Tugnoli, V.; de Grandis, D. Botulinum neurotoxins: Mechanism of action and therapeutic applications. Mol. Med. Today 1996, 2, 418-424.
13. Humeau, Y.; Doussau, F.; Grant, N.J.; Poulain, B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000, 82, 427-446.
14. Schiavo, G.; Matteoli, M.; Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80, 717-766.
15. Johnson, E.A.; Montecucco, C. Chapter 11 botulism. Handb. Clin. Neurol. 2008, 91, 333-368.
16. Montal, M. Botulinum neurotoxin: A marvel of protein design. Annu. Rev. Biochem. 2010, 79, 591-617.
17. Montecucco, C.; Rossetto, O.; Schiavo, G. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol. 2004, 12, 442-446.
18. Baldwin, M.R.; Barbieri, J.T. Association of botulinum neurotoxins with synaptic vesicle protein complexes. Toxicon 2009, 54, 570-574.
19. Brunger, A.T. Structural insights into the molecular mechanism of Ca2+-dependent exocytosis. Curr. Opin. Neurobiol. 2000, 10, 293-302.
20. Sudhof, T.C. The synaptic vesicle cycle. Annu. Rev. Neurosci. 2004, 27, 509-547.
21. Grumelli, C.; Verderio, C.; Pozzi, D.; Rossetto, O.; Montecucco, C.; Matteoli, M. Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology 2005, 26, 761-767.
22. Turton, K.; Chaddock, J.A.; Acharya, K.R. Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility. Trends Biochem. Sci. 2002, 27, 552-557.
23. Davletov, B.; Bajohrs, M.; Binz, T. Beyond Botox: Advantages and limitations of individual botulinum neurotoxins. Trends Neurosci. 2005, 28, 446-452.
24. Verderio, C.; Rossetto, O.; Grumelli, C.; Frassoni, C.; Montecucco, C.; Matteoli, M. Entering neurons: Botulinum toxins and synaptic vesicle recycling. EMBO Rep. 2006, 7, 995-999.
25. Koussoulakos, S. Botulinum neurotoxin: The ugly duckling. Eur. Neurol. 2009, 61, 331-342.
26. Lalli, G.; Bohnert, S.; Deinhardt, K.; Verastegui, C.; Schiavo, G. The journey of tetanus and botulinum neurotoxins in neurons. Trends Microbiol. 2003, 11, 431-37.
27. Popoff, M.R.; Poulain, B. Bacterial toxins and the nervous system: Neurotoxins and multipotential toxins interacting with neuronal cells. Toxins 2010, 2, 683-737.
28. Sanchez-Prieto, J.; Sihra, T.S.; Evans, D.; Ashton, A.; Dolly, J.O.; Nicholls, D.G. Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes. Eur. J. Biochem. 1987, 165, 675-681.
29. Ashton, A.C.; Dolly, J.O. Characterization of the inhibitory action of botulinum neurotoxin type A on the release of several transmitters from rat cerebrocortical synaptosomes. J. Neurochem. 1988, 50, 1808-1816.
30. McMahon, H.T.; Foran, P.; Dolly, J.O.; Verhage, M.; Wiegant, V.M.; Nicholls, D.G. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J. Biol. Chem. 1992, 267, 21338-21343.
31. Blasi, J.; Binz, T.; Yamasaki, S.; Link, E.; Niemann, H.; Jahn, R. Inhibition of neurotransmitter release by clostridial neurotoxins correlates with specific proteolysis of synaptosomal proteins. J. Physiol. Paris 1994, 88, 235-241.
32. Hausinger, A.; Volknandt, W.; Zimmermann, H.; Habermann, E. Inhibition by clostridial neurotoxins of calcium-independent [3H]noradrenaline outflow from freeze-thawed synaptosomes: Comparison with synaptobrevin hydrolysis. Toxicon 1995, 33, 1519-1530.
33. Williamson, L.C.; Halpern, J.L.; Montecucco, C.; Brown, J.E; Neale, E.A. Clostridial neurotoxins and substrate proteolysis in intact neurons. Botulinum neurotoxin C acts on synaptosomal-associated protein of 25 kDa. J. Biol. Chem. 1996, 271, 7694-7699.
34. Keller, J.E.; Cai, F.; Neale, E.A. Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 2004, 43, 526-532.
35. Foran, P.G.; Mohammed, N.; Lisk, G.O.; Nagwaney, S.; Lawrence, G.W.; Johnson, E.; Smith, L.; Aoki, K.R.; Dolly, J.O. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations on inhibition of exocytosis in central neurons. J. Biol. Chem. 2003, 278, 1363-1371.
36. Horton, N.; Quick, M.W. Syntxin 1-A up-regulates GABA transporter expression by subcellular redistribution. Mol. Membr. Biol. 2001, 18, 39-44.
37. Foran, P.; Lawrence, G.; Dolly, J.O. Blockade by botulinum neurotoxin B of catecholamine release from adrenochromaffin cells correlates with its cleavage of synaptobrevin and a homologue present on the granules. Biochemistry 1995, 34, 5494-5503.
38. 2+ partially rescues synaptic transmission in hippocampal cultures treated with botulinum toxin A and C, but not tetanus toxin. J. Neurosci. 1997, 17, 7190-7202.
39. Bergquist, F.; Niazi, H.S.; Nissbrandt, H. Evidence for different exocytosis pathways in dendritic and terminal dopamine release in vivo. Brain Res. 2002, 950, 245-253.
40. Zhu, G.; Okada, M.; Yoshida, S.; Hirose, S.; Kaneko, S. Determination of exocytosis mechanisms of DOPA in rat striatum using in vivo microdialysis. Neurosci. Lett. 2004, 367, 241-245.
41. Fortin, G.D.; Desrosiers, C.C.; Yamaguchi, N.; Trudeau, L.E. Basal somatodendritic dopamine release requires snare proteins. J. Neurochem. 2006, 96, 1740-1749.
42. Murakami, T.; Okada, M.; Kawata, Y.; Zhu, G.; Kamata, A.; Kaneko, S. Determination of effects of antiepileptic drugs on SNAREs-mediated hippocampal monoamine release using in vivo microdialysis. Br. J. Pharmacol. 2001, 134, 507-520.
43. Jeftinija, S.D.; Jeftinija, K.V.; Stafanovic, G. Cultured astrocytes express proteins involved in vescicular glutamate release. Brain Res. 1997, 750, 41-47.
44. Verderio, C.; Coco, S.; Rossetto, O.; Montecucco, C.; Matteoli, M. Internalization and proteolytic action of botulinum toxins in CNS neurons and astrocytes. J. Neurochem. 1999, 73, 372-379.
45. Araque, A.; Li, N.; Doyle, R.T.; Haydon, P.G. SNARE protein-dependent glutamate release from astrocytes. J. Neurosci. 2000, 20, 666-673.
46. Ishikawa, H.; Mitsui, Y.; Yoshitomi, T.; Mashimo, K.; Aoki, S.; Mukuno, K.; Shimizu, K. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn. J. Ophthalmol. 2000, 44, 106-109.
47. Welch, M.J.; Purkiss, J.R.; Foster, K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000, 38, 245-258.
48. Purkiss, J.; Welch, M.; Doward, S.; Foster, K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem. Pharmacol. 2000, 59, 1403-1406.
49. Hou, Y.P.; Zhang, Y.P.; Song, Y.F.; Zhu, C.M.; Wang, Y.C.; Xie, G.L. Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo. Can. J. Physiol. Pharmacol. 2007, 85, 209-214.
50. Durham, P.L.; Cady, R.; Cady, R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache 2004, 44, 35-43.
51. Chuang, Y.C.; Yoshimura, N.; Huang, C.C.; Chiang, P.H.; Chancellor, M.B. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J. Urol. 2004, 172, 1529-1532.
52. Rapp, D.E.; Turk, K.W.; Bales, G.T.; Cook, S.P. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J. Urol. 2006, 175, 1138-1142.
53. Meng, J.; Wang, J.; Lawrence, G.; Dolly, J.O. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J. Cell. Sci. 2007, 120, 2864-2874.
54. Lucioni, A.; Bales, G.T.; Lotan, T.L.; McGehee, D.S.; Cook, S.P.; Rapp, D.E. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008, 101, 366-370.
55. Meng, J.; Ovsepian, S.V.; Wang, J.; Pickering, M.; Sasse, A.; Aoki, K.R.; Lawrence, G.W.; Dolly, J.O. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J. Neurosci. 2009, 29, 4981-4992.
56. Gobel, H.; Heinze, A.; Heinze-Khun, K.; Austermannn, K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 2001, 91, 195-199.
57. Ashkenazi, A. Botulinum toxin type a for chronic migraine. Curr. Neurol. Neurosci. Rep. 2010, 10, 140-146.
58. Brin, M.F.; Fahn, S.; Moskowitz, C.; Friedman, A.; Shale, H.M.; Greene, P.E.; Blitzer, A.; List, T.; Lange, D.; Lovelace, R.E. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv. Neurol. 1988, 50, 599-608.
59. Tarsy, D.; First, E.R. Painful cervical dystonia: Clinical features and response to treatment with botulinum toxin. Mov. Disord. 1999, 14, 1043-1045.
60. Freund, B.; Schwartz, M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J. Pain 2003, 4, 159-165.
61. Mense, S. Neurobiological basis for the use of botulinum toxin in pain therapy. J. Neurol. 2004, 251, I/1-I/7.
62. Cui, M.; Khanijou, S.; Rubino, J.; Aoki, K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107, 125-133.
63. Porro, C.A.; Cavazzuti, M. Spatial and temporal aspects of spinal cord and brainstem activation in the formalin pain model. Prog. Neurobiol. 1993, 41, 565-607.
64. Aoki, K.R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003, 43, S9-S15.
65. Aoki, K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005, 26, 785-793.
66. Luvisetto, S.; Marinelli, S.; Lucchetti, F.; Marchi, F.; Cobianchi, S.; Rossetto, O.; Montecucco, C.; Pavone, F. Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. Brain Res. 2006, 1082, 124-131.
67. Verderio, C.; Pozzi, D.; Pravettoni, E.; Inverardi, F.; Schenk, U.; Coco, S.; Proux-Gillardeaux, V.; Galli, T.; Rossetto, O.; Frassoni, C.; Matteoli, M. SNAP-25 modulation of calcium dynamics underlies differences in GABAergic and glutamatergic responsiveness to depolarization. Neuron 2004, 41, 599-610.
68. Frassoni, C.; Inverardi, F.; Coco, S.; Ortino, B.; Grumelli, C.; Pozzi, D.; Verderio, C.; Matteoli, M. Analysis of SNAP-25 immunoreactivity in hippocampal inhibitory neurons during development in culture and in situ. Neuroscience 2005, 131, 813-823.
69. Verderio, C.; Grumelli, C.; Raiteri, L.; Coco, S.; Paluzzi, S.; Caccin, P.; Rossetto, O.; Bonanno, G.; Montecucco, C.; Matteoli, M. Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 2007, 8, 142-153
70. Grumelli, C.; Corradini, I.; Matteoli, M.; Verderio, C. Intrinsic calcium dynamics control botulinum toxin A susceptibility in distinct neuronal populations. Cell Calcium 2010, 47, 419-424.
71. Bach-Rojecky, L.; Lacković, Z. Antinociceptive effect of botulinum toxin type A in rat model of carrageenan and capsaicin induced pain. Croat. Med. J. 2005, 46, 201-208.
72. Bach-Rojecky, L.; Dominis, M.; Lacković, Z. Lack of anti-inflammatory effect of botulinum toxin type A in experimental models of inflammation. Fundam. Clin. Pharmacol. 2008, 22, 503-509.
73. Favre-Guilmard, C.; Auguet, M.; Chabrier, P.E. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur. J. Pharmacol. 2009, 617, 48-53.
74. Carmichael, N.M.; Dostrovsky, J.O.; Charlton, M.P. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. Pain 2010, 149, 316-324.
75. Chuang, Y.C.; Yoshimura, N.; Huang, C.C.; Chiang, P.H.; Chancellor, M.B. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J. Urol. 2004, 172, 1529-1532.
76. Chuang, Y.C.; Yoshimura, N.; Huang, C.C.; Wu, M.; Chiang, P.H.; Chancellor, M.B. Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and infpresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur. Urol. 2009, 56, 159-166.
77. Chuang, Y.C.; Yoshimura, N.; Huang, C.C.; Wu, M.; Chiang, P.H.; Chancellor, M.B. Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and infpresses prostatic pain on capsaicin induced prostatitis model in rat. J. Urol. 2008, 180, 742-748.
78. Chancellor, M.B.; Fowler, C.J.; Apostolidis, A.; de Groat, W.C.; Smith, C.P.; Somogyi, G.T.; Aoki, K.R. Drug Insight: Biological effects of botulinum toxin A in the lower urinary tract. Nat. Clin. Pract. Urol. 2008, 5, 319-328.
79. Klein, A.W. The therapeutic potential of botulinum toxin. Dermatol. Surg. 2004, 30, 452-455.
80. Mogil, J.S. Animal model of pain: Progress and challenge. Nature Rev. Neurosci. 2009, 10, 283-294.
81. Wang, L.X.; Wang, Z.J. Animal and cellular model of chronic pain. Adv. Drug Deliv. Rev. 2003, 55, 949-965.
82. Wall, P.D.; Devor, M.; Inbal, R.; Scadding, J.W.; Schonfeld, D.; Seltzer, Z.; Tomkiewicz, M.M. Autotomy following peripheral nerve lesions: Experimental anaesthesia dolorosa. Pain 1979, 7, 103-111.
83. Lindenlaub, T.; Sommer, C. Partial sciatic nerve transection as a model of neruopathic pain: A qualitative and quantitative neuropathological study. Pain 2000, 89, 97-106.
84. Bennett, G.J.; Xie, Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33, 87-107.
85. Seltzer, Z.; Dubner, R; Shir, Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990, 43, 205-218.
86. Kim, S.H.; Chung, J.M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992, 50, 355-363.
87. Bach-Rojecky, L.; Relja, M.; Lacković, Z. Botulinum toxin type A in experimental neuropathic pain. J. Neural. Transm. 2005, 112, 215-219.
88. Park, H.J.; Lee, Y.; Lee, J.; Park, C.; Moon, D.E. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can. J. Anaesth. 2006, 53, 470-477.
89. Luvisetto, S.; Marinelli, S.; Cobianchi, S.; Pavone, F. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience 2007, 14, 1-4.
90. Luvisetto, S.; Marinelli, S.; Cobianchi, S.; Makuch, W.; Obara, I.; Przewlocka, B.; Pavone, F. Botulimun neurotoxin serotype A and B differently modulate neuropathic pain in animal models. FENS. Abstr. 2008, 4, 055.18.
91. Marinelli, S.; Luvisetto, S.; Cobianchi, S.; Makuch, W.; Obara, I.; Mezzaroma, E.; Caruso, M.; Straface, E.; Przewlocka, B.; Pavone, F. Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience 2010, 171, 316-328.
92. Vargas, M.E.; Barres, B.A. Why is wallerian degeneration in the CNS so slow? Annu. Rev. Neurosci. 2007, 30, 153-179.
93. Mika, J.; Korostynski, M.; Kaminska, D.; Wawrzczak-Bargiela, A.; Osikowicz, M.; Makuch, W.; Przewlocki, R.; Przewlocka, B. Interleukin-1αhas antiallodynic and antihyperalgesic activities in a rat neuropathic pain model. Pain 2008, 138, 587-597.
94. Gupta, R.; Rummler, L.S.; Palispis, W.; Truong, L.; Chao, T.; Rowshan, K.; Mozaffar, T.; Steward, O. Local down-regulation of myelin-associated glycoprotein permits axonal sprouting with chronic nerve compression injury. Exp. Neurol. 2006, 200, 418-29.
95. de la Hoz, C.L.; Oliveira, A.L.; Queiroz, L.S.; Langone, F. Wallerian degeneration in C57BL/6J and A/J mice: Differences in time course of neurofilament and myelin breakdown, macrophage recruitment and iNOS expression. J. Anat. 2003, 203, 567-578.
96. Pines, J. Four-dimensional control of the cell cycle. Nat. Cell. Biol. 1999, 1, 73-79.
97. Manes, T.; Zheng, D.Q.; Tognin, S.; Woodard, A.S.; Marchisio, P.C.; Languino, L.R. Alpha(v)beta3 integrin expression up-regulates Cdc2, which modulates cell migration. J. Cell. Biol. 2003, 161, 817-826.
98. Han, I.S.; Seo, T.B.; Kim, K.H.; Yoon, J.H.; Yoon, S.J.; Namgung, U. Cdc2-mediated Schwann cell migration during peripheral nerve regeneration. J. Cell Sci. 2007, 120, 246-255.
99. Bhatheja, K.; Field, J. Schwann cells: Origins and role in axonal maintenance and regeneration. Int. J. Biochem. Cell Biol. 2006, 38, 1995-1999.
100. Hayashi, A.; Koob, J.W.; Liu, D.Z.; Tong, A.Y.; Hunter, D.A.; Parsadanian, A.; Mackinnon, S.E.; Myckatyn, T.M. A double-transgenic mouse used to track migrating Schwann cells and regenerating axons following engraftment of injured nerves. Exp. Neurol. 2007, 207, 128-138.
101. Jessen, K.R.; Mirsky, R. The origin and development of glial cells in peripheral nerves. Nat. Rev. Neurosci. 2005, 6, 671-682.
102. Triolo, D.; Dina, G.; Lorenzetti, I.; Malaguti, M.; Morana, P.; del Carro, U.; Comi, G.; Messing, A.; Quattrini, A.; Previtali, S.C. Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage. J. Cell Sci. 2006, 119, 3981-3993.
103. Mika, J.; Rojewska, E.; Makuch, W.; Korostynski, M.; Luvisetto, S.; Marinelli, S.; Pavone, F.; Przewlocka, B. The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord. Neuroscience 2010, doi:10.1016/j.neuroscience.2010.11.040.
104. Vos, B.P.; Strassman, A.W.; Maciewicz, R.J. Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat's infraorbital nerve. J. Neurosci. 1994, 14, 2708-2723.
105. Kitamura, Y.; Matsuka, Y.; Spigelman, I.; Ishihara, Y.; Yamamoto, Y.; Sonoyama, W.; Kamioka, H.; Yamashiro, T.; Kuboki, T.; Oguma, K. Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience 2009, 159, 1422-1429.
106. Calcutt, N.A. Experimental models of painful diabetic neuropathy. J. Neurol. Sci. 2004, 220, 137-139.
107. Bach-Rojecky, L.; Salković-Petrisić, M.; Lacković, Z. Botulinum toxin type A reduces pain infersensitivity in experimental diabetic neuropathy: Bilateral effect after unilateral injection. Eur. J. Pharmacol. 2010, 633, 10-14.
108. Mahowald, M.L.; Krug, H.E.; Singh, J.A.; Dykstra, D. Intra-articular botulinum toxin type A: A new approach to treat arthritis joint pain. Toxicon 2009, 54, 658-667.
109. Krug, H.E.; Frizelle, S.; McGarraugh, P.; Mahowald, M.L. Pain behavior measures to quantitate joint pain and response to neurotoxin treatment in murine models of arthritis. Pain Med. 2009, 10, 1218-1228.
110. Pogatzki, E.M.; Niemeir, J.S.; Brennan, T.J. Persistent secondary hyperalgesia after gastrocnemius incision in rat. Eur. J. Pain 2002, 6, 295-305.
111. Filipović, B.; Bach-Rojecky, L.; Lacković, Z. Lasting reduction of postsurgical hyperalgesia after single injection of botulinum toxin type A in rat. Fundam. Clin. Pharmacol. 2010, 24, 43-45.
112. Habermann, E. 125I-labeled neurotoxin from Clostridium botulinum A: Preparation, binding to synaptosomes and ascent to the spinal cord. Naunyn Schmiedebergs Arch. Pharmacol. 1974, 281, 47-56.
113. Wiegand, H.; Erdmann, G., Wellhöner, H.H. 125I-labelled botulinum A neurotoxin: Pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch. Pharmacol. 1976, 292, 161-165.
114. Black, J.D.; Dolly, J.O. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J. Cell Biol. 1986, 103, 521-534.
115. Antonucci, F.; Rossi, C.; Gianfranceschi, L.; Rossetto, O.; Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J. Neurosci. 2008, 28, 3689-3696.
116. Bach-Rojecky, L.; Lacković, Z. Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol. Biochem. Behav. 2009, 94, 234-238.
117. Currà, A.; Berardelli, A. Do unintended actions of botulinum toxin at distant sites have clinical implications? Neurology 2009, 72, 1095-1099.
118. Caleo, M.; Antonucci, F.; Restani, L.; Mazzocchio, R. A reappraisal of the central effects of botulinum neurotoxin type A: By what mechanism? J. Neurochem. 2009, 109, 15-24.
119. Pickett, A. Re-engineering clostridial neurotoxins for treatment of chronic pain. Biodrugs 2010, 24, 173-182.
120. Chaddock, J.A.; Purkiss, J.R.; Friis, L.M.; Broadbridge, J.D.; Duggan, M.J.; Fooks, S.J.; Shone, C.C.; Quinn, C.P.; Foster, K.A. Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A. Infect. Immun. 2000, 68, 2587-2593.
121. Chaddock, J.A.; Purkiss, J.R.; Duggan, M.J.; Quinn, C.P.; Shone, C.C.; Foster, K.A. A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors 2000, 18, 147-155.
122. Duggan, M.J.; Quinn, C.P.; Chaddock, J.A.; Purkiss, J.R.; Alexander, F.C.; Doward, S.; Fooks, S.J.; Friis, L.M.; Hall, Y.H.; Kirby, E.R.; Leeds, N.; Moulsdale, H.J.; Dickenson, A.; Green, G.M.; Rahman, W.; Suzuki, R.; Shone, C.C.; Foster, K.A. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J. Biol. Chem. 2002, 277, 34846-34852.
123. Chaddock, J.A.; Purkiss, J.R.; Alexander, F.C.; Doward, S.; Fooks, S.J.; Friis, L.M.; Hall, Y.H.; Kirby, E.R.; Leeds, N.; Moulsdale, H.J.; Dickenson, A.; Green, G.M.; Rahman, W.; Suzuki, R.; Duggan, M.J.; Quinn, C.P.; Shone, C.C.; Foster, K.A. Retargeted clostridial endopeptidases: Inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain. Mov. Disord. 2004, 19, S42-S47.
124. Sutton, J.M.; Wayne, J.; Scott-Tucker, A.; O'Brien, S.M.; Marks, P.M.; Alexander, F.C.; Shone, C.C.; Chaddock, J.A. Preparation of specifically activatable endopeptidase derivatives of Clostridium botulinum toxins type A, B, and C and their applications. Protein Expr. Purif. 2005, 40, 31-41.
125. Foster, K.A.; Adams, E.J.; Durose, L., Cruttwell, C.J.; Marks, E.; Shone, C.C.; Chaddock, J.A.; Cox, C.L.; Heaton, C.; Sutton, J.M.; Wayne, J.; Alexander, F.C.; Rogers, D.F. Re-engineering the target specificity of Clostridial neurotoxins-A route to novel therapeutics. Neurotox. Res. 2006, 9, 101-107.
126. Baptista, A.F.; de Souza Gomes, J.R.; Oliveira, J.T.; Santos, S.M.G.; Vannier-Santos, M.A.; Martinez, A.M.B. A new approach to assess function after sciatic nerve lesion in the mouse-Adaptation of the sciatic static index. J. Neurosci. Meth. 2007, 161, 259-264